Last updated on March 2019

Immune Disorder HSCT Protocol


Brief description of study

This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders. A regimen that maximizes host immune suppression is expected to reduce graft rejection and optimize donor cell engraftment.

Clinical Study Identifier: NCT01821781

Find a site near you

Start Over

Washington University

Saint Louis, MO United States
  Connect »

Methodist Heathcare

San Antonio, TX United States
  Connect »